Business
Vir Biotechnology Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, February 24, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,00
About this update from Vir Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3057,"height":718,"url":"https://media.zenfs.com/en/business-wire.com/81691994f615a298718e342c9d2f5744"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QRAdXr9TTlrviFF6P.tFtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/81691994f615a298718e342c9d2f5744","width":960,"height":225},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XTCKm0._ziw8MZTauYfPHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/81691994f615a298718e342c9d2f5744","width":1200,"height":282}},"lazy":false},{"type":"text","content":"SAN FRANCISCO, February 24, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Vir Biotechnology. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":903,"tagName":"p"},{"type":"text","content":"Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers for the offering.","length":126,"tagName":"p"},{"type":"text","content":"The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission, or the SEC, on November 3, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, by contacting: Goldman Sachs & Co. LLC, Attn: Prospectus Department,...